Perspectives on Nonalcoholic Fatty Liver Disease:An Overview of Present and Future Therapies

作     者：John Vizuete Alfredo Camero Mazyar Malakouti Karthik Garapati Julio Gutierrez 

作者机构：Department of MedicineDivision of GastroenterologyUniversity of Texas Health Science Center San AntonioSan AntonioTXUSA The Texas Liver InstituteSan AntonioTXUSA 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2017年第5卷第1期

页      面：67-75页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：AbbVieAbbVie Synageva Bristol-Myers SquibbBristol-Myers Squibb Gilead Sciences, Inc.Gilead Sciences Intercept JanssenJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc MerckMerck & Company 

主　　题：Nonalcoholic fatty liver disease Fatty liver Steatohepatitis NAFLD NAFL NASH Developmental drugs Hepatic steatosis 

摘      要：Nonalcoholic fatty liver disease(NAFLD)represents a major public health *** therapies for this condition are scarce,but multiple agents with novel mechanisms of action are in *** we review the pathophysiology and natural history of NALFD,diagnostic testing and data for currently available treatment *** then turn our attention to promising developmental drugs and their respective *** the prevalence of fatty liver disease increases,clinicians will have more tools at hand for management of this *** conclude the horizon is bright for patients and doctors who deal with NAFLD.